

## This week in therapeutics

Indication	Target/marker/pathway	Summary	Licensing status	Publication and contact information
<b>Cancer</b>				
Cancer	Cyclin dependent kinase 4 (CDK4); CDK6	<p>Studies in cell culture identified a series of 4-(pyrazol-4-yl)-pyrimidine-based CDK4- and CDK6-selective inhibitors that could help treat cancer. In a human mantle cell lymphoma (MCL) cell line, the compounds produced dose-dependent increases in cell-cycle arrest compared with vehicle. Next steps could include evaluating the CDK4- and CDK6-selective inhibitors in mouse xenograft models.</p> <p>LEE011, a CDK4 and CDK6 inhibitor from Novartis AG, is in preclinical development for cancer. PD-332991, a CDK4 inhibitor from Onyx Pharmaceuticals Inc. and Pfizer Inc., is in Phase II testing for cancer.</p> <p><b>SciBX 3(46); doi:10.1038/scibx.2010.1377</b> Published online Dec. 2, 2010</p>	Patent application filed covering pyrazole derivatives; licensing status unavailable	<p>Cho, Y.S. <i>et al. J. Med. Chem.</i>; published online Nov. 1, 2010; doi:10.1021/jm100571n</p> <p><b>Contact:</b> Moo Je Sung, Novartis Institutes for BioMedical Research, Cambridge, Mass. e-mail: <a href="mailto:mooje.sung@novartis.com">mooje.sung@novartis.com</a></p> <p><b>Contact:</b> Young Shin Cho, same affiliation as above e-mail: <a href="mailto:youngshin.cho@novartis.com">youngshin.cho@novartis.com</a></p>